Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vanda Pharmaceuticals Inc. VNDA
$6.22
+$0.02 (0.24%)
На 18:00, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
361036169.00000000
-
week52high
11.90
-
week52low
5.75
-
Revenue
254382000
-
P/E TTM
24831
-
Beta
0.70103800
-
EPS
0.11000000
-
Last Dividend
0.00000000
-
Next Earnings Date
01 авг 2023 г. в 10:59
Описание компании
Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs. The company's marketed products include HETLIOZ for the treatment of non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its products under development include HETLIOZ (tasimelteon) for the treatment of jet lag disorder, smith-magenis syndrome, pediatric Non-24, autism spectrum, and delayed sleep phase disorder; Fanapt (iloperidone) for the treatment of bipolar disorder and a long acting injectable formulation program for the treatment of schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist, for the treatment of atopic dermatitis, gastroparesis, and motion sickness. The company's products under development also comprise VTR-297, a small molecule histone deacetylase inhibitor for the treatment of hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist for the treatment of psychiatric disorders; a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors for the treatment of dry eye and ocular inflammation, as well as BPO-27 for the treatment of secretory diarrhea disorders, including cholera; and VHX-896, the active metabolite of iloperidone. It markets its products in the United States, Europe, and Israel. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Hold | Buy | 25 февр 2022 г. |
| B of A Securities | Buy | 12 мая 2021 г. | |
| Citigroup | Neutral | Buy | 14 янв 2021 г. |
| Citigroup | Buy | Neutral | 29 окт 2020 г. |
| Citigroup | Neutral | Buy | 09 июн 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Williams Timothy | D | 87551 | 8000 | 15 дек 2022 г. |
| Moran Kevin Patrick | D | 0 | 7500 | 06 дек 2022 г. |
| Moran Kevin Patrick | D | 120160 | 4792 | 06 дек 2022 г. |
| Moran Kevin Patrick | A | 124952 | 7500 | 06 дек 2022 г. |
| Polymeropoulos Mihael Hristos | D | 0 | 75365 | 06 дек 2022 г. |
| Polymeropoulos Mihael Hristos | D | 1406866 | 48250 | 06 дек 2022 г. |
| Polymeropoulos Mihael Hristos | A | 1455116 | 75365 | 06 дек 2022 г. |
| Polymeropoulos Mihael Hristos | D | 75365 | 74635 | 05 дек 2022 г. |
| Polymeropoulos Mihael Hristos | D | 1379751 | 47650 | 05 дек 2022 г. |
| Polymeropoulos Mihael Hristos | A | 1427401 | 74635 | 05 дек 2022 г. |
Новостная лента
Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023
PRNewsWire
27 апр 2023 г. в 18:00
Conference Call and Webcast to Follow WASHINGTON , April 27, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the first quarter 2023 on Wednesday, May 3, 2023, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, May 3, 2023, during which management will discuss the first quarter 2023 financial results and other corporate activities.
Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2022 Financial Results on February 8, 2023
PRNewsWire
01 февр 2023 г. в 18:30
Conference Call and Webcast to Follow WASHINGTON , Feb. 1, 2023 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the fourth quarter and full year 2022 on Wednesday, February 8, 2023, after the market closes. Vanda will host a conference call at 4:30 PM ET on Wednesday, February 8, 2023, during which management will discuss the fourth quarter and full year 2022 financial results and other corporate activities.
Vanda Pharmaceuticals Announces Participation at November 2022 Investor Conferences
PRNewsWire
08 ноя 2022 г. в 20:30
WASHINGTON , Nov. 8, 2022 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November 2022: The Stifel 2022 Healthcare Conference on Tuesday, November 15, 2022. A corporate presentation is scheduled for 10:20 a.m.
Vanda Pharmaceuticals Inc. (VNDA) Q3 2022 Earnings Call Transcript
Seeking Alpha
02 ноя 2022 г. в 22:35
Vanda Pharmaceuticals Inc. (NASDAQ:VNDA ) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Kevin Moran - Senior Vice President & Chief Financial Officer Mihael Polymeropoulos - President & Chief Executive Officer Tim Williams - General Counsel Conference Call Participants Operator Good afternoon. My name is Abba and I will be your conference operator today.
Vanda Pharmaceuticals (VNDA) Lags Q3 Earnings and Revenue Estimates
Zacks Investment Research
02 ноя 2022 г. в 18:52
Vanda (VNDA) delivered earnings and revenue surprises of -40% and 8%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?